YU2503A - Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina - Google Patents

Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina

Info

Publication number
YU2503A
YU2503A YU2503A YUP2503A YU2503A YU 2503 A YU2503 A YU 2503A YU 2503 A YU2503 A YU 2503A YU P2503 A YUP2503 A YU P2503A YU 2503 A YU2503 A YU 2503A
Authority
YU
Yugoslavia
Prior art keywords
oxygenated esters
oxygenated
esters
iodo phenylamino
acids
Prior art date
Application number
YU2503A
Other languages
English (en)
Inventor
Stephen Douglas Barret
Cathlin Biwersi
Michael D. Kaufman
Haile Tecle
Joseph Scott Warmus
Michael Huai Gu Chen
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of YU2503A publication Critical patent/YU2503A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Ovaj pronalazak se odnosi na derivate kiseoničnih estara 4-jonofenilamino-benzhidroksaminske kiseline, na farmaceutske preparate i postupke za njihovu upotrebu. Ovaj pronalazak se takodje odnosi na kristalne oblike derivata kiseoničnih estara 4-jodofenilamino-benzhidroksaminske kiseline, na farmaceutske preparate i na postupke za njihovu upotrebu.[The present invention relates to oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof. The present invention also relates to crystaline forms of oxygenated esters of 4- iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof.
YU2503A 2000-07-19 2001-07-12 Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina YU2503A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21937200P 2000-07-19 2000-07-19

Publications (1)

Publication Number Publication Date
YU2503A true YU2503A (sh) 2006-05-25

Family

ID=22819013

Family Applications (1)

Application Number Title Priority Date Filing Date
YU2503A YU2503A (sh) 2000-07-19 2001-07-12 Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina

Country Status (42)

Country Link
US (2) US6960614B2 (sh)
EP (1) EP1301472B1 (sh)
JP (1) JP3811775B2 (sh)
KR (1) KR100773621B1 (sh)
CN (1) CN1219753C (sh)
AP (2) AP2003002742A0 (sh)
AR (2) AR033542A1 (sh)
AU (2) AU7349801A (sh)
BG (1) BG66386B1 (sh)
BR (1) BRPI0112584B8 (sh)
CA (1) CA2416685C (sh)
CZ (1) CZ303815B6 (sh)
DK (1) DK1301472T3 (sh)
DZ (1) DZ3401A1 (sh)
EA (1) EA005818B1 (sh)
EC (1) ECSP034430A (sh)
EE (1) EE05450B1 (sh)
ES (1) ES2461854T3 (sh)
GE (1) GEP20053496B (sh)
GT (1) GT200100141A (sh)
HR (1) HRP20030083A2 (sh)
HU (1) HU230251B1 (sh)
IL (1) IL153817A0 (sh)
IS (1) IS6666A (sh)
MA (1) MA26930A1 (sh)
MY (1) MY151458A (sh)
NO (1) NO328436B1 (sh)
NZ (1) NZ524120A (sh)
OA (1) OA12333A (sh)
PA (1) PA8522601A1 (sh)
PE (1) PE20020664A1 (sh)
PL (1) PL203387B1 (sh)
PT (1) PT1301472E (sh)
SI (1) SI1301472T1 (sh)
SK (1) SK288317B6 (sh)
SV (1) SV2002000563A (sh)
TN (1) TNSN01108A1 (sh)
TW (1) TWI311551B (sh)
UA (1) UA76425C2 (sh)
WO (1) WO2002006213A2 (sh)
YU (1) YU2503A (sh)
ZA (1) ZA200300348B (sh)

Families Citing this family (224)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU2503A (sh) * 2000-07-19 2006-05-25 Warner-Lambert Company Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20030008807A1 (en) * 2001-06-14 2003-01-09 The Regents Of The University Of California Novel signaling pathway for the production of inflammatory pain and neuropathy
BR0307060A (pt) 2002-01-23 2004-10-26 Warner Lambert Co ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
DOP2003000613A (es) 2002-03-13 2003-09-30 Array Biopharma Inc Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole derivatives as mek inhibitors)
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US20060178323A1 (en) * 2002-04-09 2006-08-10 Buxton Francis P Methods for the treatment of chronic pain and compositions therefor
WO2004045617A1 (en) * 2002-11-15 2004-06-03 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
US7378233B2 (en) 2003-04-12 2008-05-27 The Johns Hopkins University BRAF mutation T1796A in thyroid cancers
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US8084645B2 (en) * 2003-09-19 2011-12-27 Chugai Seiyaku Kabushiki Kaisha 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
CA2542210A1 (en) * 2003-10-21 2005-05-06 Warner-Lambert Company Llc Polymorphic form of n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
KR101099849B1 (ko) 2003-11-19 2011-12-28 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
NZ590160A (en) 2003-11-21 2012-07-27 Array Biopharma Inc AKT protein kinase inhibitors
UA89035C2 (ru) * 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
BRPI0509580A (pt) * 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
CA2727841A1 (en) 2004-06-11 2005-12-22 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido [2, 3-d] pyrimidine derivatives and related compounds
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
EP1781285A2 (en) * 2004-08-18 2007-05-09 Merck & Co., Inc. Mitotic kinesin inhibitors
KR101318012B1 (ko) 2004-10-20 2013-10-14 메르크 세로노 에스.에이. 3-아릴아미노 피리딘 유도체
WO2006061712A2 (en) * 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
UA100007C2 (ru) 2005-05-18 2012-11-12 Астразенека Аб Гетероциклические ингибиторы мек, их применение и фармацевтическая композиция, которая их содержит
WO2006134469A1 (en) * 2005-06-14 2006-12-21 Warner-Lambert Company Llc Methods of preparing mek inhibitor
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
CN109053523B (zh) * 2005-10-07 2022-03-25 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek抑制剂的吖丁啶
WO2007042885A2 (en) * 2005-10-07 2007-04-19 Pfizer Products Inc. Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
WO2007054556A1 (de) 2005-11-11 2007-05-18 Æterna Zentaris Gmbh Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
CN101516891B (zh) 2006-07-06 2013-06-05 阵列生物制药公司 作为akt蛋白激酶抑制剂的二氢噻吩并嘧啶
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN103288753A (zh) 2006-07-06 2013-09-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的环戊二烯并[d]嘧啶
ZA200901009B (en) * 2006-08-21 2010-05-26 Genentech Inc Aza-benzothiophenyl compounds and methods of use
KR101475088B1 (ko) 2006-08-21 2014-12-23 제넨테크, 인크. 아자-벤조티오페닐 화합물 및 사용 방법
EP2069354B1 (en) * 2006-08-21 2011-11-02 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
RU2444524C2 (ru) * 2006-08-21 2012-03-10 Дженентек, Инк. Азабензотиофенильные соединения и способы применения
NZ577047A (en) 2006-10-23 2011-02-25 Takeda Pharmaceutical Mapk/erk kinase inhibitors
JP5311673B2 (ja) * 2006-12-14 2013-10-09 エグゼリクシス， インコーポレイテッド Ｍｅｋ阻害剤の使用方法
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
EP2164850B1 (en) 2007-06-12 2016-01-13 Genentech, Inc. N-substituted azaindoles and methods of use
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
CA2692502C (en) 2007-07-05 2016-03-01 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
KR101624361B1 (ko) 2007-07-05 2016-05-25 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
CA2706571C (en) * 2007-12-19 2012-11-27 Genentech, Inc. 5-anilinoimidazopyridines and methods of use
PT2231662E (pt) 2007-12-19 2011-09-12 Genentech Inc 8-anilinoimidazopiridinas e o seu uso como agentes anticancerígenos e/ou anti-inflamatórios
MX2010006331A (es) 2007-12-20 2010-07-05 Hoffmann La Roche Hidantoinas sustituidas como inhibidores de cinasa mek.
EP2220092B1 (en) 2007-12-21 2012-06-06 Genentech, Inc. Azaindolizines and methods of use
RU2504542C2 (ru) 2008-01-09 2014-01-20 Эррэй Биофарма Инк. Гидроксилированные пиримидилциклопентаны в качестве ингибиторов протеинкиназы (акт)
ES2401685T3 (es) 2008-01-09 2013-04-23 Array Biopharma, Inc. Pirimidil ciclopentano hidroxilado como inhibidor de la proteína quinasa AKT
WO2009093008A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
EP2307364B1 (en) 2008-07-01 2013-06-19 Genentech, Inc. Isoindolone derivatives as mek kinase inhibitors and methods of use
PE20110570A1 (es) 2008-07-01 2011-08-26 Genentech Inc Heterociclos biciclicos sustituidos
EA018539B1 (ru) 2008-08-04 2013-08-30 Мерк Патент Гмбх Фениламино-изоникотинамидные соединения
US8350026B2 (en) 2008-08-27 2013-01-08 Leo Pharma A/S VEGF-2 receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof
US8278105B2 (en) * 2008-09-09 2012-10-02 University Of Southern California Induction, propagation and isolation of liver progenitor cells
ES2399384T3 (es) 2008-11-10 2013-04-01 Bayer Schering Pharma Ag Sulfonamido fenoxibenzamidas sustituidas
JP5651125B2 (ja) 2008-12-10 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異
EP2475659B1 (en) 2009-09-08 2015-10-28 F.Hoffmann-La Roche Ag 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
MX2012003546A (es) * 2009-09-23 2012-09-07 Glaxosmithkline Llc Combinacion.
MX345155B (es) * 2009-10-12 2017-01-18 F Hoffmann-La Roche Ag * Combinaciones de un inhibidor de pi3k y un inhibidor de mek.
EP2491014A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
EP2491015A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
EP2491016A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
ES2627703T3 (es) 2010-01-22 2017-07-31 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Inhibidores de PI3·quinasa
EP2536720A1 (en) 2010-02-18 2012-12-26 Centro Nacional de Investigaciones Oncológicas (CNIO) Triazolo [4, 5 - b]pyridin derivatives
MX360932B (es) 2010-02-25 2018-11-21 Dana Farber Cancer Inst Inc Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
EA030276B1 (ru) 2010-03-09 2018-07-31 Дана-Фарбер Кэнсер Инститьют, Инк. Способы идентификации страдающих раком пациентов и лечения рака у пациентов, у которых имеется или развивается резистентность к первой терапии рака
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
RU2439053C1 (ru) * 2010-08-03 2012-01-10 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" Диариламины и способ их получения
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
JP2013542214A (ja) 2010-10-29 2013-11-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換フェノキシピリジン類
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
CA2822638C (en) 2010-12-22 2021-02-16 Fate Therapeutics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
CN102649773A (zh) * 2011-02-23 2012-08-29 苏州波锐生物医药科技有限公司 氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途
JP6147246B2 (ja) 2011-04-01 2017-06-14 ジェネンテック， インコーポレイテッド Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
MY179607A (en) 2011-04-01 2020-11-11 Genentech Inc Combinations of akt inhibitor compounds and abiraterone, and methods of use
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
CA2872979C (en) 2011-05-19 2020-02-18 Joaquin Pastor Fernandez Macrocyclic compounds as protein kinase inhibitors
WO2012162293A1 (en) * 2011-05-23 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
US9833439B2 (en) 2011-05-25 2017-12-05 Universite Paris Descartes ERK inhibitors for use in treating spinal muscular atrophy
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
US9416132B2 (en) 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
KR20140072028A (ko) 2011-08-31 2014-06-12 노파르티스 아게 Pi3k- 및 mek-억제제의 상승작용적 조합물
WO2013067165A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
CN102532089B (zh) * 2011-12-22 2014-05-14 凯莱英医药集团（天津）股份有限公司 一种制备手性甘油醇缩丙酮的方法
WO2013105022A2 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
CN103204822B (zh) 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
HK1206611A1 (en) 2012-05-31 2016-01-15 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
PE20191818A1 (es) 2012-10-12 2019-12-27 Exelixis Inc Proceso para la elaboracion de 1-({3,4-difluoro-2-[(2-fluoro-4-yodofenil)amino]fenil}carbonil)-3-[(2s)-piperidin-2-il]azetidin-3ol
ES2644758T3 (es) 2012-10-16 2017-11-30 Tolero Pharmaceuticals, Inc. Moduladores de PKM2 y métodos para su uso
CA2889381C (en) * 2012-11-15 2023-01-03 Duquesne University Of The Holy Ghost Carboxylic acid ester prodrug inhibitors of mek
DK2925366T3 (en) 2012-11-29 2018-06-06 Novartis Ag PHARMACEUTICAL COMBINATIONS
EP2752191A1 (en) 2013-01-07 2014-07-09 Sanofi Compositions and methods using hdm2 antagonist and mek inhibitor
US10139415B2 (en) 2013-02-27 2018-11-27 Daiichi Sankyo Company, Limited Method for predicting responsiveness to compound inhibiting MAPK signal transduction pathway
US9611258B2 (en) 2013-03-13 2017-04-04 The Regents Of The University Of Michigan Dual MEK/PI3K inhibitors and therapeutic methods using the same
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
EP3466431B1 (en) * 2013-03-14 2023-11-15 MSD International GmbH Crystalline forms and methods for preparing sglt2 inhibitors
KR20210149232A (ko) 2013-03-14 2021-12-08 스미토모 다이니폰 파마 온콜로지, 인크. Ｊａｋ2 및 ａｌｋ2 억제제 및 이들의 사용 방법
CN105007950B (zh) 2013-03-15 2019-01-15 诺华股份有限公司 抗体药物缀合物
EP3043822A1 (en) 2013-09-11 2016-07-20 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Compositions for preparing cardiomyocytes
CA2923835C (en) 2013-09-11 2022-11-29 The Administrators Of The Tulane Educational Fund Novel anthranilic amides and the use thereof
DK3068393T5 (da) 2013-11-11 2022-08-22 Amgen Inc Kombinationsterapi som inkluderer en mdm2-inhibitor og et eller flere yderligere farmaceutisk aktive midler til behandlingen af kræftformer
US20160340407A1 (en) 2014-01-14 2016-11-24 Dana-Farber Camcer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
CN104788365B (zh) * 2014-01-16 2018-08-10 上海艾力斯医药科技有限公司 异烟酰胺衍生物、其制备方法及应用
PT3114214T (pt) 2014-03-04 2024-01-03 Fate Therapeutics Inc Métodos de reprogramação melhorados e plataformas de cultura celular
US10023879B2 (en) 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
CA2954599A1 (en) 2014-08-12 2016-02-18 Novartis Ag Anti-cdh6 antibody drug conjugates
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
RU2718914C2 (ru) 2014-09-13 2020-04-15 Новартис Аг Сочетанные способы лечения с использованием ингибиторов alk
JP2017535528A (ja) 2014-10-03 2017-11-30 ノバルティス アーゲー 組み合わせ治療
EP3204516B1 (en) 2014-10-06 2023-04-26 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
ES2987508T3 (es) 2014-11-14 2024-11-15 Novartis Ag Conjugados de anticuerpos y fármacos
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
JP6736559B2 (ja) 2014-12-23 2020-08-05 ノバルティス アーゲー トリアゾロピリミジン化合物およびその使用
JP6800859B2 (ja) 2015-01-26 2020-12-16 フェイト セラピューティクス，インコーポレイテッド 造血細胞分化を誘導するための方法および組成物
KR20170129757A (ko) 2015-03-25 2017-11-27 노파르티스 아게 Fgfr4 억제제로서의 포르밀화 n-헤테로시클릭 유도체
MA41866A (fr) 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
CN104906081A (zh) * 2015-05-25 2015-09-16 上海中医药大学附属曙光医院 一种化合物在制备治疗骨关节炎药物中的应用
WO2016203432A1 (en) 2015-06-17 2016-12-22 Novartis Ag Antibody drug conjugates
CA2992221C (en) 2015-08-28 2023-06-27 Novartis Ag Mdm2 inhibitors and combinations thereof
JP7263005B2 (ja) 2015-10-16 2023-04-24 フェイト セラピューティクス，インコーポレイテッド 基底状態の多能性の誘導及び維持に関するプラットフォーム
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
KR20250033315A (ko) 2015-11-04 2025-03-07 페이트 세러퓨틱스, 인코포레이티드 조혈 세포 분화를 유도하기 위한 방법 및 조성물
SG11201803144WA (en) 2015-11-04 2018-05-30 Fate Therapeutics Inc Genomic engineering of pluripotent cells
CN105646438A (zh) * 2015-12-22 2016-06-08 天津大学 一种缩酮类糖醇基小分子凝胶因子及其制备方法和应用
WO2017127755A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
US11096964B2 (en) 2016-01-20 2021-08-24 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20180118719A (ko) 2016-03-04 2018-10-31 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
EP3472166A1 (en) 2016-06-20 2019-04-24 Novartis AG Imidazopyrimidine compounds useful for the treatment of cancer
JP2019522049A (ja) 2016-06-20 2019-08-08 ノバルティス アーゲー トリアゾロピリジン化合物及びその使用
EP3472168B1 (en) 2016-06-20 2024-01-10 Novartis AG Crystalline forms of triazolopyrimidine compound
WO2018009638A1 (en) 2016-07-06 2018-01-11 The Regents Of The University Of Michigan MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME
ES2974991T3 (es) 2016-09-19 2024-07-02 Novartis Ag Combinaciones terapéuticas que comprenden un inhibidor de RAF y un inhibidor de ERK
WO2018092064A1 (en) 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
JP7098615B2 (ja) 2016-12-05 2022-07-11 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
WO2018146253A1 (en) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
US11179413B2 (en) 2017-03-06 2021-11-23 Novartis Ag Methods of treatment of cancer with reduced UBB expression
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
AU2018262891B2 (en) 2017-05-02 2021-04-01 Novartis Ag Combination therapy
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
US20200362058A1 (en) 2017-05-24 2020-11-19 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
CA3075046A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
WO2019099838A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
HUE067430T2 (hu) 2018-03-19 2024-10-28 Taiho Pharmaceutical Co Ltd Nátrium-laurilszulfátot tartalmazó gyógyászati készítmény
EP3773591A4 (en) 2018-04-05 2021-12-22 Sumitomo Dainippon Pharma Oncology, Inc. AXL KINASE INHIBITORS AND THEIR USE
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
JP7369719B2 (ja) 2018-06-12 2023-10-26 アムジエン・インコーポレーテツド ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
HRP20231295T1 (hr) 2018-07-10 2024-02-02 Novartis Ag Derivati 3-(5-hidroksi-1-oksoizoindolin-2-il)piperidin-2,6-diona i njihova upotreba u liječenju bolesti ovisnih o cinkovom prstu 2 (ikzf2) obitelji ikaros
PT3826686T (pt) 2018-07-25 2025-08-04 Advanced Accelerator Applications S A Soluções estáveis de complexo de radionuclídeo concentrado
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
AU2019310590A1 (en) 2018-07-26 2021-01-14 Sumitomo Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
DK3837256T3 (da) 2018-08-17 2023-05-30 Novartis Ag Ureaforbindelser og sammensætninger som smarca2/brm-atpase-hæmmere
JP7358484B2 (ja) 2018-09-25 2023-10-10 アドヴァンスド・アクセラレーター・アプリケーションズ・（イタリー）・エッセエッレエッレ 併用療法
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN113412262A (zh) 2019-02-12 2021-09-17 大日本住友制药肿瘤公司 包含杂环蛋白激酶抑制剂的制剂
JP7483732B2 (ja) 2019-02-15 2024-05-15 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113747895A (zh) 2019-03-22 2021-12-03 大日本住友制药肿瘤公司 包含pkm2调节剂的组合物和用其治疗的方法
AU2020276695A1 (en) 2019-05-13 2021-12-23 Novartis Ag New crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer
UA129871C2 (uk) 2019-05-21 2025-08-27 Емджен Інк. Тверді форми
JP2022539208A (ja) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー， インコーポレイテッド チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
EP4025215A1 (en) 2019-09-02 2022-07-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of pyrvinium for the treatment of a ras pathway mutated acute myeloid leukemia
US20220280509A1 (en) 2019-09-26 2022-09-08 Novartis Ag Aza-quinoline compounds and uses thereof
US20230056470A1 (en) 2019-12-20 2023-02-23 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
TW202200146A (zh) 2020-04-10 2022-01-01 日商大鵬藥品工業股份有限公司 使用有3,5-二取代苯炔基化合物與mek抑制劑之癌症治療法
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
BR112022026202A2 (pt) 2020-06-23 2023-01-17 Novartis Ag Regime de dosagem compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
CN116134027B (zh) 2020-08-03 2025-01-24 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
AR123185A1 (es) 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
CA3206906A1 (en) 2021-02-02 2022-08-11 Andras Herner Selective bcl-xl protac compounds and methods of use
WO2022177556A1 (en) 2021-02-17 2022-08-25 Warner-Lambert Company Llc Compositions of essentially pure form iv of n-((r)-2,3- dihydroxypropoxy)-3,4-difluoro-2- (2-fluoro-4-iodophenylamino)- benzamide and uses thereof
IL305079A (en) 2021-02-17 2023-10-01 Springworks Therapeutics Inc Dispersible formulations of N-((R)-3,2-dihydroxypropoxy)-4,3-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and their uses
US11084780B1 (en) 2021-02-17 2021-08-10 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11066358B1 (en) 2021-02-17 2021-07-20 Warner-Lambert Company Llc Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
MX2023009560A (es) * 2021-02-17 2023-10-25 Springworks Therapeutics Inc Solidos cristalinos del inhibidor de mek n-((r)-2,3-dihidroxipropo xi)-3,4-difluoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida y sus usos.
US11571402B2 (en) 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US20240310266A1 (en) 2021-03-18 2024-09-19 Novartis Ag Biomarkers for cancer and methods of use thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
US12037346B2 (en) 2021-04-13 2024-07-16 Nuvalent, Inc. Amino-substituted heteroaryls for treating cancers with EGFR mutations
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CN114524753B (zh) * 2022-02-24 2024-03-26 安徽大学 一种多取代异羟肟酸衍生物的合成方法
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
US20250228812A1 (en) 2022-03-17 2025-07-17 Springworks Therapeutics, Inc. Fluorinated phenylamino compounds and pharmaceutical compositions
WO2023209611A1 (en) 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
EP4526286A1 (en) 2022-05-17 2025-03-26 Assia Chemical Industries Ltd. Solid state forms of mirdametinib and process for preparation thereof
CN119604315A (zh) 2022-05-20 2025-03-11 诺华股份有限公司 Epha2 bcl-xl抑制剂抗体-药物缀合物及其使用方法
TW202404645A (zh) 2022-05-20 2024-02-01 瑞士商諾華公司 Met bcl-xl抑制劑抗體-藥物結合物及其使用方法
WO2024023666A1 (en) 2022-07-26 2024-02-01 Novartis Ag Crystalline forms of an akr1c3 dependent kars inhibitor
WO2024189481A1 (en) 2023-03-10 2024-09-19 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
AU2024236271A1 (en) 2023-03-16 2025-09-25 SpringWorks Therapeutics Inc. Dosage forms of mirdametinib
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4368207A (en) * 1977-05-31 1983-01-11 Block Drug Company Inc. Higher alcohol toxicants effective against insects
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
US5783202A (en) * 1995-03-14 1998-07-21 Soltec Research Pty. Ltd. Pediculicidal mousse composition for killing head lice
AU5610398A (en) * 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
JP2002511092A (ja) * 1997-07-01 2002-04-09 ワーナー−ランバート・コンパニー ４−ブロモまたは４−ヨードフェニルアミノベンズヒドロキサム酸誘導体およびそのｍｅｋ阻害剤としての使用
DE69836378T2 (de) 1997-07-01 2007-10-11 Warner-Lambert Co. Llc Benzoesäure- und Benzamid-Derivate von Anthranilsäure und ihre Anwendung als MEK-Inhibitoren
AU1549700A (en) 1998-12-04 2000-06-26 Neurosearch A/S Ion channel modulating agents
WO2000035435A1 (en) 1998-12-15 2000-06-22 Warner-Lambert Company Use of a mek inhibitor for preventing transplant rejection
WO2000035436A2 (en) 1998-12-16 2000-06-22 Warner-Lambert Company Treatment of arthritis with mek inhibitors
ID30250A (id) 1998-12-22 2001-11-15 Warner Lambert Co Kemoterapi kombinasi
US6054493A (en) 1998-12-30 2000-04-25 The Lubrizol Corporation Emulsion compositions
AU2203800A (en) * 1999-01-07 2000-07-24 Warner-Lambert Company Antiviral method using mek inhibitors
WO2000040235A2 (en) 1999-01-07 2000-07-13 Warner-Lambert Company Treatment of asthma with mek inhibitors
JP2001055376A (ja) 1999-01-13 2001-02-27 Warner Lambert Co ジアリールアミン
CA2355470C (en) 1999-01-13 2008-09-30 Warner-Lambert Company Benzoheterocycles and their use as mek inhibitors
KR20020012315A (ko) 1999-07-16 2002-02-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법
ATE449764T1 (de) 1999-12-28 2009-12-15 Pharmacopeia Inc Cytokine, insbesondere tnf-alpha, hemmer
YU2503A (sh) * 2000-07-19 2006-05-25 Warner-Lambert Company Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina

Also Published As

Publication number Publication date
AR097445A2 (es) 2016-03-16
AP2001002217A0 (en) 2001-09-30
PL203387B1 (pl) 2009-09-30
PT1301472E (pt) 2014-05-15
GT200100141A (es) 2002-05-28
MA26930A1 (fr) 2004-12-20
HK1055943A1 (en) 2004-01-30
EE05450B1 (et) 2011-08-15
HUP0302781A2 (hu) 2003-12-29
BG107564A (bg) 2003-09-30
US20050176820A1 (en) 2005-08-11
SK288317B6 (sk) 2015-11-03
ES2461854T3 (es) 2014-05-21
NZ524120A (en) 2005-08-26
AP2003002742A0 (en) 2003-03-31
EE200300030A (et) 2004-10-15
NO20030249D0 (no) 2003-01-17
PE20020664A1 (es) 2002-08-23
CA2416685C (en) 2008-10-07
SK422003A3 (en) 2003-11-04
JP2004504294A (ja) 2004-02-12
BR0112584A (pt) 2003-06-17
AU2001273498B2 (en) 2006-08-24
EP1301472B1 (en) 2014-03-26
US6960614B2 (en) 2005-11-01
BRPI0112584B8 (pt) 2021-05-25
GEP20053496B (en) 2005-04-25
WO2002006213A2 (en) 2002-01-24
ZA200300348B (en) 2004-04-13
OA12333A (en) 2004-04-06
HU230251B1 (hu) 2015-11-30
DK1301472T3 (da) 2014-04-07
SV2002000563A (es) 2002-08-26
BG66386B1 (bg) 2013-11-29
EA005818B1 (ru) 2005-06-30
MY151458A (en) 2014-05-30
EA200300065A1 (ru) 2003-10-30
CN1219753C (zh) 2005-09-21
PL365775A1 (en) 2005-01-10
PA8522601A1 (es) 2003-05-14
NO328436B1 (no) 2010-02-22
JP3811775B2 (ja) 2006-08-23
KR20030059077A (ko) 2003-07-07
HUP0302781A3 (en) 2013-06-28
CZ303815B6 (cs) 2013-05-15
SI1301472T1 (sl) 2014-05-30
KR100773621B1 (ko) 2007-11-05
IL153817A0 (en) 2003-07-31
DZ3401A1 (fr) 2002-01-24
NO20030249L (no) 2003-02-12
US20040054172A1 (en) 2004-03-18
UA76425C2 (en) 2006-08-15
CZ200369A3 (cs) 2003-08-13
CN1446197A (zh) 2003-10-01
TWI311551B (en) 2009-07-01
TNSN01108A1 (en) 2005-11-10
BRPI0112584B1 (pt) 2018-09-18
WO2002006213A3 (en) 2002-05-23
ECSP034430A (es) 2003-03-10
EP1301472A2 (en) 2003-04-16
AU7349801A (en) 2002-01-30
US7411001B2 (en) 2008-08-12
HRP20030083A2 (en) 2003-04-30
IS6666A (is) 2002-12-31
AR033542A1 (es) 2003-12-26
CA2416685A1 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
YU2503A (sh) Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina
WO2002094210A3 (de) Kosmetische mittel
AU2002346392A1 (en) Acid sanitizing and cleaning compositions containing protonated carboxylic acids
AU2482800A (en) Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
DOP2001000224A (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester.
UY27619A1 (es) Ésteres hidroxamato del ácido n-(4-fenil sustituido)- antranílico
EE04990B1 (et) HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod
TW200513267A (en) Collagen production enhancer and use and preparation thereof
AR024944A1 (es) Amidas de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y su preparacion
PA8559401A1 (es) Sales de acido succinico de 5,7,14-triazatetraciclo (10.3.1.0 2,11.0 4, 9)-hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas.
UY27618A1 (es) Ésteres hidroxamato de ácido n-(4-fenil-sustituido)-antranílico
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
WO2002076970A3 (en) Tocopherol succinate derivatives and compositions
MXPA02012889A (es) Esteres de acidos 4-alcoxi-ciclohexano-1-amino-carboxilicos y procedimiento para su obtencion.
RS63804A (en) Stable salts of o-acetylsalicylic acid containing basic amino acids ii
WO2005006860A3 (en) Azole derivatives and methods for making the same
DE50002065D1 (de) Haarpflegemittel
NO20022361L (no) Fremgangsmåte for fremstilling av konjugert linolsyre
EE200300406A (et) Meetod loomasööda lisandina kasutatava D-pantoteenhappe ja/või tema soolade saamiseks
EE200300405A (et) Meetod loomasööda lisandina kasutatava D-pantoteenhappe ja/või tema soolade saamiseks
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
DOP2001000214A (es) Esteres oxigenados de acidos 4-yodo benzhidroxamicos (oxigenated esters of 4-yodo phenylamino benzhydroxamic acids
ATE514426T1 (de) Formulierungen zur verringerung oder eliminierung der toxizität von umwelthormonen mit ursodesoxycholsäure
AU2003289782A1 (en) Valproic acid analogues and pharmaceutical compositions thereof
CY1115042T1 (el) Οξυγονωμενοι εστερες 4-ιωδοφαινυλαμινοβενζυδροξαμικων οξεων